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a b s t r a c t
A classic way of delaying drug resistance is to use an alternative when possible. We tested
the malaria treatment Argemone mexicana decoction (AM), a validated self-prepared tradi-
tional medicine made with one widely available plant and safe across wide dose variations.
In an attempt to reﬂect the real situation in the home-based management of malaria in
a remote Malian village, 301 patients with presumed uncomplicated malaria (median age
5 years) were randomly assigned to receive AM or artesunate-amodiaquine [artemisinin
combination therapy (ACT)] as ﬁrst-line treatment. Both treatments were well tolerated.
Over 28 days, second-line treatmentwas not required for 89% (95% CI 84.1–93.2) of patients
on AM, versus 95% (95% CI 88.8–98.3) on ACT. Deterioration to severe malaria was 1.9% in
both groups in children aged≤5 years (therewere no cases in patients aged >5 years) and0%rtemisinin combination therapy
ali
had coma/convulsions. AM, now government-approved in Mali, could be tested as a ﬁrst-
line complement to standard modern drugs in high-transmission areas, in order to reduce
the drug pressure for development of resistance to ACT, in the management of malaria.
In view of the low rate of severe malaria and good tolerability, AM may also constitute a
ﬁrst-aid treatment when access to other antimalarials is delayed.
Society© 2009 Royal
. Introduction
How could modern antimalarials such as artemisinin
ombination therapies (ACTs) be kept effective for as long
s possible, when threats of resistance are appearing?
idespread resistance to amodiaquine and sulphadoxine-
yrimethamine already exists.1,2 There is also some
∗ Corresponding author. Present address: IUMSP-UEPP, Bugnon
7-1000 Lausanne, Switzerland. Tel.: +41 21 314 69 46;
ax: +41 21 314 72 44.
E-mail address: bertrand.graz@chuv.ch (B. Graz).
035-9203/$ – see front matter © 2009 Royal Society of Tropical Medicine and H
oi:10.1016/j.trstmh.2009.07.005of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All
rights reserved.
evidence of resistance developing to lumefantrine in
areas where artemether-lumefantrine is widely used.3
Resistancewill continue to spread, particularly to the long-
acting partner drugs, if ACTs are squandered on patients
who do not absolutely need them.
Because 80% of malaria patients never go to a health
facility, and treat themselves at home,4 WHOhas been pro-
moting the home-based management of malaria (HMM)
with ACTs as ﬁrst-line treatment.5,6 In most of sub-
Saharan Africa, diagnostic facilities are not available or cost
effective, so cases of fever are treated presumptively,7,8
although many of these patients may not need treatment
with an ACT. If the HMM strategy is implemented, it will
ygiene. Published by Elsevier Ltd. All rights reserved.
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The exclusion criteria were: (1) severe malaria; (2) historyFigure 1. Argemone mexicana L. (Papaveraceae). Photo by Dr Jacques
Falquet.
lead to the very widespread use of ACTs, and a greatly
increased risk of resistance.
A classic way of delaying resistance is to use an alterna-
tive for all but the most vulnerable cases. Local, traditional
resourcesmightbe an interesting solution if theyhavebeen
in use for several generations and are still clinically effec-
tive locally, as it is probable that they will not lose their
effectiveness rapidly. A strategy for a semi-immune pop-
ulation, using such a traditional product as ﬁrst line with
an ACT as second line, would reduce the likelihood of, and
speedof, resistance developing to theACT. In fact, up to 75%
of malaria patients choose to treat themselves with herbal
remedies.9
These observations and reﬂections led to the elabora-
tion of the following research question: Could some local,
traditional antimalarials be of interest for themanagement
of malaria?
In an ethnomedical study in Mali, among the 66
plants used for malaria, eight were consistently associ-
ated with good clinical outcomes.10,11 These were then
tested in vitro, and the most active happened to be the
one with the best clinical correlates, a weed found in
many tropical areas: Argemone mexicana L (Papaveraceae)
(Figure 1).
Argemone mexicana is a pantropical weed with a long
history of use in traditional medicine, dating back to
the Aztecs.12 It is used as an antimalarial in several
African countries, including Benin, Mali and Sudan.13–15
Its in-vitro efﬁcacy against Plasmodium falciparum has
been conﬁrmed: the IC50 (concentration which inhibits
50% of parasites) values of the aerial parts of this plant,
against the chloroquine-resistant K1 strain of P. falci-
parum, were 5.89 and1.00g/ml for the aqueous decoction
and methanol extracts, respectively.11 A prospective dose
escalating clinical trial of Argemone mexicana decoction
(AM) following a local recipe, in patients with uncom-
plicated malaria, found a dose-response correlation and
a good safety proﬁle.16 In addition to its promising pro-
ﬁle, we observed that AM was often readily available
where and when modern drugs of acceptable quality were
not.11ical Medicine and Hygiene 104 (2010) 33–41
The purpose of this studywas to compare two strategies
for the home-based management of presumed uncompli-
cated malaria: AM as ﬁrst line with ACT as second line,
versus ACT as ﬁrst line.
2. Materials and methods
When designing this research project, the dilemma
was whether to design a randomised controlled trial (RCT)
in standard experimental conditions or to study the real
situation (at least, ‘as real as possible’). A standard RCTwith
patients meeting WHO research criteria would have pro-
vided an estimate of the magnitude of outcome differences
between ACT and AM in an experimental setting. However,
Malian medical and public health authorities were more
interested in a real-situation estimate, the primary aim
being to produce the basic knowledge necessary for issu-
ing a new ‘médicament traditionnel amélioré’ (improved
traditional drug), with a reasonable estimate of the effects
to be anticipated when used outside of clinical settings
and, most of the time, without laboratory diagnosis. So
we had to agree a priori (based on health-policy grounds)
what difference between AM and ACT would be acceptable
in a ‘real-life’ setting (= delta). We then designed a study
to test whether the observed difference was greater or
smaller than the set delta.
2.1. Setting
This study was conducted in conditions as close to the
‘real world’ as possible, in the village of Missidougou, in
the southeast of Mali. The village is located 40km from
the nearest Malian primary health centre, and 70km from
the nearest hospital (Sikasso). This includes a 25km dirt
track, along which there is no public transport. The village
chief of Missidougou is a traditional healer, and his son
has trained both with him and as a health-care assistant.
He fulﬁls the role of a village health worker. The trial was
undertaken during the peak malaria season, from late July
to early December, 2006.
2.2. Participants
Patients ﬁrst consulted the village health worker. He
referred to the study team all patients whom he presumed
to have malaria (mainly on the basis of a history of
fever and no other obvious disease). The study was then
explained to the patients. There was an information sheet,
which was read and translated to the patients and their
parents in the local language, as most were illiterate.
Subjects (or their parents in the case of children) gave
individual written consent, usually with a ﬁngerprint, as
most could not sign their name.
We included as many patients as possible with pre-
sumptive malaria, in order to obtain a realistic assessment
of management in the hands of a village health worker.of ingestion of a full dose of antimalarial on the same day;
(3) lack of consent; (4) inability to return for follow-up; (5)
ingestion of antimalarials not prescribed by the study team
during the course of follow-up.
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Patients whom the village health worker or traditional
ealer could not treat were referred to the medical team
or a consultation.
.3. Design
Patients were randomly assigned to two groups, AM or
CT, using a computer-generated random number table
nd a 2:1 randomisation ratio with blocks of 6 stratiﬁed for
ge (<1 year, 1–5 years, >5 years).17 Owing to the very dif-
erent nature of the two treatments, it was not possible to
lind the patients or the clinicians to the treatments being
aken. A small survey was undertaken to record treatment
references in the research team and villagers.
Patients were followed up on days 3, 7, 14 and 28 and
ere advised to return at any time if they experienced a
eterioration of their condition, or recurrence of symp-
oms. Patients were assessed by a medical doctor (history
nd physical examination). Thin and thick blood ﬁlmswere
aken at baseline and at every follow-up visit. Haematocrit
as measured at baseline and on day 28, and in cases of
reatment failure.
.4. Treatment interventions
.4.1. AM group
Argemone mexicana aerial parts were harvested and
ried in the shade, mostly in the spring of 2006. The plant
s very well known locally, and the risk of confusion with
ther species is very low, thanks to its characteristic yel-
ow ﬂowers, spiny leaves and yellowmilky latex (Figure 1).
atients were given a bag of 500g of the dried plant mate-
ial, and the method of preparation was explained to them
or to the accompanying person, in the case of children) by
he village health worker (who is also a traditional healer).
atients were advised to divide the dried herb into two
arts, and to boil one part in about 2.5 l of water (just
nough to cover the driedmaterial) for about 3h, thenﬁlter
nd keep in a clean, covered pot for a maximum of 4 days.
he recommended regimen is a twice-daily dose, ranging
n volume from a tea glass (ca. 60 ml) for infants to a coffee
lass (ca. 300 ml) for adults. It is also recommended, for
nfants and small children, to apply the preparation to the
kin (‘washing’) twice a day.
Patients were advised to take this treatment for 1 week.
f at the end of the ﬁrst week the patient had largely
mproved but was still experiencing a few symptoms such
s a mild fever, they were given the treatment for a second
eek.
In cases of treatment failure, patients were given oral
rtesunate/amodiaquine, or intramuscular artemether if
nable to swallow, or referred if appropriate. Treatment
ailure was deﬁned as a worsening of the clinical condi-
ion, development of danger signs (inability to drink or
reastfeed; vomiting everything; recent history of convul-
ions; lethargy or unconsciousness; prostration), or failure
o improve with persistent fever.
.4.2. ACT group
Patients were given artesunate (50mg) and amodi-
quine (153mg) tablets in a co-blister pack (Arsucam,ical Medicine and Hygiene 104 (2010) 33–41 35
Sanoﬁ-Synthelabo Group, Casablanca, Morocco) by the
village health worker. The dose was determined by
the patient’s weight, according to the following dosage
schedule: <10kg, ½+½; 10–20kg, 1 +1; 21–40kg, 2 +2;
>40kg, 4 +4, twice daily for 3days. For small children
the tablets were crushed and mixed with sugar and a
small amount of water. Women known to be pregnant at
baseline were treated with sulphadoxine-pyrimethamine
(three tablets in a single dose) instead of artesunate-
amodiaquine. In cases of treatment failure patients were
given oral artemether-lumefantrine (Coartem Novartis,
Basel, Switzerland), or intramuscular artemether if unable
to swallow, or were referred if appropriate.
2.4.3. Both groups
Theﬁrst administrationof themedicinewasobserved in
most cases, especially in patients who complained of vom-
iting. Sugar was added to increase palatability for young
children. The dose was repeated if the patient vomited
within 30min. If vomiting persisted the patient was given
an intramuscular injection of artemether.
Any necessary additional treatment was given by the
village healthworker and themedical team as appropriate,
and was recorded in the patient’s notes. In cases of acute
severe illness (whether or not related to malaria) patients
were referred to the regional hospital.
2.5. Laboratory methods
A ﬁeld laboratory was installed in the village, using
solar panels and car batteries to power a microscope and
centrifuge. Blood ﬁlms were stained with 3% Giemsa for
40min, and parasite counts were done using standard
WHO7 criteria. All blood ﬁlms taken at baseline and on the
day of a presumed new episode of malaria were checked
by a second experienced microscopist (MLW). In addition,
quality control was undertaken by a third independent
expert microscopist (Dr Mouctar Diallo, Malaria Research
and Training Centre, Bamako, Mali). Blood ﬁlms at day 28
with negative or low parasitaemia (<500/mcl) were also
double checked. As the slide may contain only one or two
parasites, which may be spotted by only one microscopist,
we decided to analyse two scenarios for parasitaemia at
day 28: ‘upper’ estimate (taking the slide to be positive
if even a single parasite was seen by one microscopist)
and ‘lower’ estimate (taking the slide to be negative unless
both microscopists conﬁrmed the presence of malaria par-
asites).
Haematocrit was measured using microhaematocrit
tubes in a centrifuge. PCR was not performed because of
ﬁnancial constraints.
Analyses of parasitaemia and haematocrit were also
used to conﬁrm whether or not the patient met the formal
WHO deﬁnitions for severe malaria.7
2.6. Outcome measuresResults were analysed by intention to treat. Patients
were excluded in the course of the study only if they
withdrew consent or if they took a course of antimalarial
medication that hadnot beenprescribedby the study team.
y of Trop36 B. Graz et al. / Transactions of the Royal Societ
The primary endpoint for comparison was ‘clinical
recovery’ at day28 without need for re-treatment with
the second-line antimalarial. Secondary endpoints were:
absence of fever at days 14 and 28, incidence of severe
malaria (which is a predictor of malaria mortality),18,19
incidence of new episodes of malaria, change in haema-
tocrit between days 0 and 28, incidence and severity of
adverse events, and parasitaemia at day 28.
2.7. Statistical analysis
The study was designed as a ‘non-inferiority’ trial. The
non-inferiority range between the two strategies (= ‘min-
imally important difference’, in terms of health policy)
was set after consultation with national health authori-
ties (malaria and public-health programmes) at 15% for the
primary endpoint.
Sample size was computed in order to assess with 80%
power and 95% conﬁdence level that AM is ‘non-inferior’
to ACT, i.e. according to the set non-inferiority range of
15% and incidence assumptions of at least 85% not needing
re-treatment with ACT. Data were entered and analysed
using Epi Info 5.01 (CDC, Atlanta, GA, USA) and SPSS 11.0
(SPSS Inc., Chicago, IL, USA) software. Comparisonof group-
speciﬁc results were assessed using the 2 test for linear
trend. Multivariate analysis of potential confounding fac-
tors (mainly age, parasitaemia, haematocrit and baseline
temperature) was not performed because there was no
signiﬁcant imbalance between the groups at baseline.
2.8. Ethical issuesThe toxicological assessment of AM was completed
according to international recommendations20 and
national regulations. Patients were included only if they
(or in the case of children, their parents) gave written
informed consent. They were free to withdraw consent at
Figure 2. Flow of patients (with a 2:1 raical Medicine and Hygiene 104 (2010) 33–41
any time. Patients were followed closely, and were given
alternative treatment if necessary. Patients who did not
return for follow-up were visited at home. All treatments
were provided free of charge, including referral to hospital
when necessary.
3. Results
3.1. Patients
From 29 July to 8 September 2006, 301 patients were
included in the study. Twelve patients were excluded at
baseline: six because of severe malaria; three were unable
to return for follow-up; two refused to give consent; and
onehad started a course of antimalarial treatment the same
day.
Of the 301 patients included, 199 were randomly
assigned to the AM group and 102 to the ACT group (ratio
2:1). Three were excluded before day 14 (two took another
antimalarial, one withdrew consent) and one on day 24
(took another antimalarial). For the purposes of the analy-
ses below, the ﬁrst three patients have been excluded from
all analyses, and the fourth only from analyses of variables
at day 28. No patients were lost to follow-up (Figure 2).
3.2. Baseline characteristics
As shown in Table 1, there were no important differ-
ences between the two groups in baseline characteristics.
Many children had no measured fever at the time of inclu-
sion, despite a diagnosis of malaria by the village health
worker.The blood ﬁlm was positive for malaria parasites in
the majority of patients (87–88%). Of those with a posi-
tive blood ﬁlm (257), only six (2%) did not have a pure P.
falciparum infection. Four had a mixed infection (P. falci-
parum+ another species), one had a P. malariae infection
ndomisation ratio).
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Table 1
Baseline characteristics of 298 patients, all diagnosed as ‘malaria patients’ by the village health worker
AM group (n=197)a ACT group (n=101)a P-value
Sex (% of males) 49.2 42.6 0.3
Median age (years) (quartiles) 5 (2–20) 5 (2–20) 0.6
Median weight (kg) (quartiles) 18.0 (9–55) 18.0 (10–46) 0.9
Median weight/age ratio (kg/years) 5.45 5.45 0.3
Patients having taken modern antimalarial
treatment (%)
7.1 8.9 0.7
Splenomegaly present (%) 15.2 9.9 0.2
Median temperature (◦C) (quartiles) 36.7 (36.2–37.6) 37.0 (36.4–37.6) 0.3
Temperature <37.5b at day 0 71.9% 64.7% 0.2
Thick ﬁlm positive (%) 87.8 87.1 0.7
Geometric mean parasite count in patients with
positive thick ﬁlm (per mcl) (interquartile
range)
893 (85–10641) 1014 (76–11614) 0.8
Haematocrit (%)c 34.3 [155] 34.8 [72] 0.4
Malaria diagnosis conﬁrmed by medical team (%) 61.9 62.4 0.9
Fulﬁl WHO criteria (%) 17.8 17.8 0.9
A n.
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pCT: artemisinin combination therapy; AM: Argemone mexicana decoctio
AM/ACT assignment ratio 2:1.
Axillary temperature in ◦C.
Number of patients tested in square brackets.
nd one had a P. ovale/P. vivax infection. The main medical
iagnosis (taking account of each patient’s history, physi-
al examination and parasitaemia) was malaria in 62% of
ases. The most common other diagnosis was a viral infec-
ion. In otherwords, 26%of patientswere consideredby the
esearch team to have a viral or other non-malarial illness
nlikely to be related to the low level of malaria parasites
n their blood. Only 17.8% of patients in each group fulﬁlled
ll the WHO diagnostic criteria recommended for research
n uncomplicated malaria21 (temperature ≥37.5 ◦C, par-
sitaemia >2000/mcl, and no concomitant infection that
ould be the cause of the fever).
Among patients coming from Missidougou village, 55%
onsulted within 24h of onset of symptoms, compared
ith 22% of patients coming from other villages. Some
aematocrit values are missing because some of the capil-
ary tubes burst open in the centrifuge.
.3. Dosage and compliance
Although not every administration of the medicine was
bserved, patientswere asked about their compliancewith
he prescribed treatment. In the AM group and the ACT
roup 75.1 and 98.0%, respectively (P<0.001), said they
ad taken the treatment at the dose prescribed. In the ACT
roup, 2% had taken a double dose on the ﬁrst day of treat-
ent. In theAMgroup, 5.5% said that they took less than the
ose prescribed, or had missed one or more doses; 18.3%
aid theyhad takenmore than thedoseprescribed. In terms
f treatment duration, 55.3% took the decoction for exactly
days; 7.1% took it for <7 days and 37.6% took it for >7
ays (9.2% for 10–12 days, 28.0% for 13–14 days). Of those
hoprolonged their treatmentwith thedecoction, 49%had
eenadvised todo so. ProlongationofAMtreatment during
second week was associated with second-line antimalar-
al treatment in the second fortnight (7/70 second-line
mong prolonged treatment, versus 3/117 among non-
rolonged; P=0.05). However if prolongation had not been
ossible, most of these patients would have needed asecond-line treatment because of mild persistent symp-
toms.
Almost all patients used the preparation in both pro-
posed routes of administration: drinking and washing
(97.5%; only one child and four adults did not wash).
Use of adjuvant treatments was reported by 55.3% of
patients in the AM group and 43.6% in the ACT group
(P=0.055): principally paracetamol (AM 80.0%, ACT 79.5%,
P=0.95), anti-emetics (AM 1.8%, ACT 4.5%, P=0.32), ginger
(AM 10.9%, ACT 11.4%, P=0.94), antitussive preparation of
Guiera senegalensis (AM 15.5%, ACT 20.5%, P=0.1) or others
(AM 0%, ACT 2%, P=0.14).
3.4. Clinical efﬁcacy
The proportion of patients not needing treatment
with the second-line antimalarial remained under the
set non-inferiority range, i.e. under the pre-deﬁned min-
imally important difference (Table 2). Severe malaria
developed in 1.9% of patients aged ≤5 years in each
group by day 28 (there were no cases in those aged >5
years). In both patients of the AM group, this consisted
of anaemia and rapid breathing, and one had persis-
tent vomiting. The one patient of the ACT group was
repeatedly vomiting, unable to swallow the artesunate-
amodiaquine, and had worsening anaemia. The latter was
the only patient requiring admission to hospital for par-
enteral antimalarials and a transfusion. Among all severe
malaria cases (see Table 2), none had coma or convul-
sions, a deﬁnition used in other similar studies.22 No
patients died in either group during the 28 days of
follow-up.
It was already known that AM does not produce total
parasite clearance in the majority of patients.16 The pro-
portionof patientswithparasitaemia at day28was63–76%
in the AM group and 21–49% in the ACT group (lower
andupper estimates, P<0.001with both estimates). Game-
tocytes were present at day 28 in 13% of the AM group
compared with 3% of the ACT group (P=0.005). However,
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Table 2
Outcomes of treatment of uncomplicated malaria by a village health worker with Argemone mexicana decoction (AM) or artemisinin combination therapy
(ACT) as ﬁrst-line antimalarial
AM group [% (95% CI)] ACT group [% (95% CI)]
No need for second-line treatment 89.3 (84.1–93.2) 95 (88.8–98.3)
T <37.5a at day 14 93.9 (89.3–96.7) 97.0 (91.6–99.4)
T <37.5a at day 28 96.9 (93.5–98.9) 99.0 (94.6–100.0)
Severe malaria >5 years 0 (0–1.83) 0 (0–3.62)
Severe malaria (0–5 years) 1.9 (0.2–6.7) 1.9 (0.05–10.3)
Severe malaria (all ages): coma/convulsions 0 (0–1.83) 0 (0–3.62)
14.2 b b
12.8
with ACAdverse effects
New episode (day 15–28) (parasite-positive)
a Temperature in ◦C.
b Most common adverse effects: cough and diarrhoea with AM; vomiting
the number of newparasite-positive episodes did not differ
signiﬁcantly between the groups (Table 2).
Among the 17.8% of patients meeting WHO diagnos-
tic criteria for research on uncomplicated malaria, there
was a clear difference between the groups at day14, with
100% of patients on artesunate-amodiaquine achieving
an ‘adequate clinical response’, compared with 65.7% on
AM (P=0.019). This was expected from previous study
results.16 However, by day28, 17% of these patients on
artesunate-amodiaquine had experienced a new episode,
and 6% had a late treatment failure, leaving only 78% of
patients on ACT with an adequate clinical response at
day28. Of these, only 43% had a deﬁnite parasite clearance
maintained at day28 (no parasites seen by either micro-
scopist).
There was no clinically signiﬁcant difference in mean
haematocrit between groups at day 28 (AM group 34.3,
ACT group 35.7, median 34 and 36, P=0.43). However, this
overall similarity does mask a few striking changes in indi-
vidual cases: in particular in a small number of children
whose haematocrit dropped after day 0 and required the
second-line treatment.
3.5. Safety and tolerability
Overall, a similar proportion of patients experienced an
adverse event in both groups,with a trend to fewer adverse
eventswithAM(14.2%) thanwithACT (18.8%). Themajority
of adverse events were deemed to be possibly, probably or
very probably linked to the treatment (altogether 71% in
the AM group, 79% in the ACT group; P=0.67). Only one
patient in each group had to stop the treatment because
of an adverse event, which in both cases was persistent
vomiting.
Cough was signiﬁcantly more common in the AM group
(5.6 vs. 1% in the ACT group; P=0.02) and was the com-
monest adverse event in this group, along with diarrhoea.
Nausea was signiﬁcantly more common in the ACT group
(8.9 vs. 2% in the AMgroup, P=0.02). Therewas also a trend
towardsmore vomiting (8.9%) anddizziness (2%) in theACT
group (AM group: 3 and 0%, respectively).The adverse events started earlier on ACT than on AM
(mean day 2.4 vs. 5.2, P=0.017). The majority of adverse
events (89%) were graded as mild, and 11% were graded
as moderate in both groups. There were no severe adverse
events in either group.(9.7–19.9) 18.8 (11.7–27.8)
(8.4–18.3) 9.9 (4.9–17.5)
T.
Although not planned in the study protocol, a small
additional survey was conducted towards the end of the
study with the six team members and 12 villagers on pref-
erences for one treatment strategy or another. This was
donebecauseof thenon-blindednatureof the studydesign.
The teammembers showed a tendency towardsmore pref-
erences for the AM strategy than the villagers, whether
for themselves (66 vs. 58%) or for their child (83 vs. 42%).
Commonest reasons given for preference towards mod-
ern treatment were ‘cures faster’ and ‘less work’, whereas
for AM treatment it was ‘slower but better cure’ and ‘less
adverse effects’.
4. Discussion
4.1. Statement of principal ﬁndings
This study, conducted in a remote village in southeast
Mali, found that, with a decoction of Argemone mexicana
as ﬁrst-line treatment, 89% (95% CI 84.1–93.2) of patients
did not require second-line treatment during the 28-day
follow-up, compared with 95% (95% CI 88.8–98.3) among
patients treated with ACT. Deterioration to severe malaria
was 1.9% in both groups in children aged≤5 years (with 0%
coma/convulsions) and 0% >5 years. Overall, there were no
signiﬁcant differences between the groups in most of the
outcome measures, and both treatments were well toler-
ated.
4.2. Strengths and weaknesses of the study
This is the largest comparative study of a herbal anti-
malarial todate, and is theonlyone to includechildrenaged
<5 years, and to include incidence of severe malaria as an
outcome measure. The group random assignment worked
well, as evidenced by the very similar baseline character-
istics shown in Table 1. Follow-up was excellent, with no
losses, thanks to proactive case-ﬁnding of all patients who
did not return.
It was not possible to blind patients or clinicians to the
treatment being taken. The dose of AM given to patients
could not be standardised, as it was prepared at home. This
is a reﬂection of what would happen in real life if a strat-
egy with this treatment were adopted as a public-health
intervention. Dose variation is acceptable if the therapeu-
tic range is wide enough, which applies to AM. This wide
y of Trop
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herapeutic range was suspected from the ﬁrst ethnomed-
cal study, by the fact that the traditional dose regimen
ith AM is ‘to drink as much as possible’ of the prepa-
ation. The regimen chosen for this study was that with
hebest observed risk/beneﬁt proﬁle in the dose-escalating
tudy.16 In addition, almost all patients also washed with
he preparation.
Besides dosage, another important aspect of the stan-
ardisation is the phytochemical proﬁle of the plants. In
his study (awaiting the discovery of the active compounds
or more precise quality control), the quality of the plant
aterial was ensured by the principle of the ‘controlled
rigin’: all the plants used came from the region around
he village where the tested recipe came from, to max-
mise the probability of a similar content between batches.
oucher specimens have been deposited at the Depart-
ent of Traditional Medicine herbarium in Mali. Today,
he ‘médicament traditionnel amélioré’ (improved tradi-
ional drug) is prepared following the same principle, with
ts raw materials coming from the same region. Even with
drug given with milligram or microgram precision, once
t has been digested, metabolised and transported to the
herapeutic target, the plasma concentration will also vary
reatly between individuals.
The presence of a medical team in the village may have
ntroduced a bias by improving compliance in both groups,
nsuring the continued availability of all the necessary
edications, and ensuring prompt referral to hospital for
he few cases in which this was needed.
The study team found that it was necessary to prolong
he treatmentwith thedecoction for a secondweek in some
atients, who were improving but were still experiencing
ome fever at day 7. This suggests that 7 days might be
oo short as a general rule. Although re-treatment with
he second-line antimalarial was more common in those
ho prolonged their treatment, these were patients who
till had minor symptoms at day 7 (so were not randomly
elected).
In the small subgroup of patients who fulﬁlled all the
HO research criteria for uncomplicated malaria,21 the
utcomes were signiﬁcantly better in the group receiving
rtesunate-amodiaquine. However, it should be stressed
hat this subgroup only accounted for 17.8% of patients in
ach group and is only a small subset of patients treated
or presumptive ‘malaria’ where diagnostic facilities are
imited. Use of such inclusion criteria would have led
o conclusions that were not representative of the real
ituation. It is important to point out that the WHO diag-
ostic criteria for research are designed to have a very
igh speciﬁcity for clinical malaria (i.e. children under 5
earsonly,with temperature≥37.5 ◦C,parasitaemia>2000,
nd no concomitant illness). They have a low sensitivity
they excludemany patientswhowould be diagnosedwith
alaria in a clinical setting), and are not the same as the
HO diagnostic criteria for treatment,7 which state that
ny patient with malaria parasites and fever should be
reated formalaria. The latter also state that if parasitologi-
al diagnosis is not possible, the patient must be treated on
he basis of a clinical diagnosis. On this last criterion, all our
atientsﬁttedaclinical diagnosis ofmalaria, in avillage set-
ingwhereparasitological diagnosiswouldnot normally beical Medicine and Hygiene 104 (2010) 33–41 39
available. Even in settings where a parasitological diagno-
sis is available, 87–88% of our patients (with positive thick
ﬁlm) would have ﬁtted the criteria for treatment.
The classical 28-day follow-upmight be too short in this
case, as the lack of parasite clearance may predispose to
later events.
4.3. Strengths and weaknesses in relation to other
studies, discussing important differences in results
This is, to our knowledge, the ﬁrst large-scale ran-
domised controlled trial of a herbal medicine for the
home-based management of malaria. Previous trials of
the home-based management of malaria have used pre-
packaged drugs: usually chloroquine. One such trial was
conducted innearbyBurkina Faso,where the epidemiology
of malaria is very similar.22 Children (<6 years of age) who
had had an episode of fever in the previous 4 weeks had
an overall risk of developing severe malaria of 8%. Severe
malariawas deﬁned in this study as ‘fever followed by con-
vulsions or loss of consciousness’. The risk was reduced
to 5% in those receiving pre-packaged chloroquine, com-
pared to 11% in those not receiving this intervention. By
contrast, in our study, the incidence of severe malaria by
this deﬁnition was 0% in both groups. No patient devel-
oped convulsions or loss of consciousness in the 28 days of
follow-up.
Although our results are not directly comparable with
the study by Sirima et al.,22 because their study was ret-
rospective and used a different treatment, both treatments
tested in the present study were correlated with a lower
incidence of severe malaria. The high prevalence of para-
sitaemia at day28 in the ACT group could be a consequence
of signiﬁcant levels of amodiaquine resistance in this area.
4.4. Meaning of the study: possible explanations and
implications for clinicians and policymakers
This study suggests that AM as ﬁrst-line treatment
may be capable of preventing severe malaria in a high-
transmission malarious area. AM could be considered in
pilot malaria programmes for semi-immune populations,
in order to increase the rate of timely treatment and
decrease the need for ACTs (with a consequent reduction
in the risk of resistance). Delay in starting treatment is one
of the main obstacles to achieving the Abuja target of 60%
of patients being treatedwithin 24 h of onset of symptoms.
Typically under 50% of patients receive treatment within
this time.23 In this study we found that 55% of patients
sought treatment within 24 h in the village of the trial,
compared with only 22% of patients who travelled from
other villages. This emphasises the importance of home-
based (or at least village-based) management if the target
is to be met. From this study we can estimate that, in sim-
ilar conditions, 89% (95% CI 84.1–93.2) of patients could be
treated with AM without needing a second-line treatment.4.5. Unanswered questions and future research
In view of the fact that complete parasite clearance
was not achieved in most patients treated with AM, the
y of Trop40 B. Graz et al. / Transactions of the Royal Societ
question remains whether the persistent parasitaemia at
day 28 leads to an increase in new episodes of malaria,
or in anaemia in subsequent weeks or months. It was
decided that patients would therefore be followed up
to 84 days, and the results of this follow-up will be the
subject of a subsequent paper. It is also important to assess
the cost-effectiveness of both treatment strategies, taking
account of the treatment of subsequent episodes and
alternative treatments where necessary.
For AM, 7 days of treatment might be too short as a
general rule. In future studies a longer basic course of AM
should be chosen: 10 or even 14 days. Most synthetic anti-
malarials (including amodiaquine, the partner drug in the
ACT used in this study, and chloroquine) have a long half-
life, staying in the bloodstream for at least 14 days.
Further research is ongoing to identify the active prin-
ciple(s) in AM, in order to aid standardisation and quality
control, which is especially important if this preparation is
to be used in other areas.
4.6. Conclusions
In view of the low rate of observed severe malaria with
AM treatment and its good safety proﬁle, AM could now
be tested in a pilot public-health programme as a ﬁrst-line
complement to standard modern drugs for semi-immune
patients in high-transmission areas, in order to reduce the
drug pressure for development of resistance. AM may also
constitute a ﬁrst-aid treatment when access to other anti-
malarials is delayed.
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